Login to Your Account

2 Companies Stumble Over PAH; Therapies Prove Difficult

By Peter Winter

Monday, August 27, 2012
Finding next-generation treatments for pulmonary arterial hypertension (PAH) is proving to be difficult. Last week two companies made the point. Gilead Sciences Inc. terminated a Phase II trial of cicletanine for PAH due to a failure of the trial to meet its primary endpoint of improvement in exercise capacity; and Novartis AG pulled its new drug application (NDA) for QTI571 (imatinib mesylate) for PAH treatment.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription